Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer - PubMed
5 days ago
- #NSCLC
- #immune checkpoint inhibitors
- #T cells
- Circulating tumor-reactive T cells (cTR-Ts) in peripheral blood (PB) may predict immune checkpoint inhibitor (ICI) response in non-small cell lung cancer (NSCLC).
- Single-cell RNA and TCR sequencing identified cTR-Ts with specific surface markers (CD49a, CD49b, HLA-DR).
- Pre-treatment cTR-Ts in ICI responders show low CD38 expression (exhaustion marker) and transition to a TCF7+ stem-like phenotype post-treatment.
- Mouse tumor models validate cTR-T phenotypic changes post-PD-1 blockade.
- The study suggests cTR-T phenotype and transition reflect functional potential and ICI therapeutic outcomes.